Texas Permanent School Fund Has $720,000 Holdings in Momenta Pharmaceuticals, Inc. (MNTA)

Texas Permanent School Fund cut its position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 7.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,635 shares of the biotechnology company’s stock after selling 4,017 shares during the period. Texas Permanent School Fund’s holdings in Momenta Pharmaceuticals were worth $720,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Momenta Pharmaceuticals by 4.9% during the second quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after purchasing an additional 290,090 shares during the period. State Street Corp raised its stake in Momenta Pharmaceuticals by 8.1% during the second quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock worth $44,842,000 after purchasing an additional 197,978 shares during the period. Northern Trust Corp raised its stake in Momenta Pharmaceuticals by 12.1% during the second quarter. Northern Trust Corp now owns 904,238 shares of the biotechnology company’s stock worth $15,283,000 after purchasing an additional 97,893 shares during the period. Bank of New York Mellon Corp raised its stake in Momenta Pharmaceuticals by 6.7% during the third quarter. Bank of New York Mellon Corp now owns 897,784 shares of the biotechnology company’s stock worth $16,609,000 after purchasing an additional 56,748 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Momenta Pharmaceuticals by 2.7% during the second quarter. Dimensional Fund Advisors LP now owns 746,397 shares of the biotechnology company’s stock worth $12,614,000 after purchasing an additional 19,882 shares during the period. 93.01% of the stock is currently owned by institutional investors.

In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 35,666 shares of Momenta Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total transaction of $503,247.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Bruce Leicher sold 1,861 shares of Momenta Pharmaceuticals stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $16.00, for a total transaction of $29,776.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 112,331 shares of company stock valued at $1,721,810. Company insiders own 4.40% of the company’s stock.

A number of equities analysts have commented on MNTA shares. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Stifel Nicolaus reaffirmed a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. Finally, Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. Momenta Pharmaceuticals has a consensus rating of “Hold” and an average price target of $15.30.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at $16.05 on Friday. Momenta Pharmaceuticals, Inc. has a 12-month low of $11.85 and a 12-month high of $19.46.

WARNING: “Texas Permanent School Fund Has $720,000 Holdings in Momenta Pharmaceuticals, Inc. (MNTA)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/18/texas-permanent-school-fund-has-720000-holdings-in-momenta-pharmaceuticals-inc-mnta.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply